Johnson & Johnson pledges 100M coronavirus vaccine doses to U.S. for $10 each NIH to test COVID-19 antibodies in hospitalized patients—starting with Eli Lilly’s CVS Health's Merlo touts 'acceleration' in company's healthcare delivery model as profits soar Gilead's COVID med remdesivir is scarce and costly, AGs say, urging feds to sidestep its patents We're looking for the most influential people in the fight against COVID-19 Moderna prices coronavirus shot at up to $37 per dose for small deals. What will big customers get? Humana's Broussard: Why COVID-19 is making a clear case for Medicare Advantage Biopharma roundup: Moderna vaccine protects mice in challenge trial; Vaccine prices vary widely Healthcare roundup: NIH launches new AI effort to fight COVID Teladoc to take over Livongo in $18.5B digital health deal Fighting COVID-19 by luring the virus away from human cells with a decoy target India’s Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test From telehealth visits to digital pharmacies, seniors have ramped up technology use during COVID-19: survey Regeneron rises on Eylea, Dupixent strength as COVID-19 antibody funding pours in Bayer's struggle to find Vitravki patients highlights broader diagnostics hurdles in pharma, likely exacerbated by COVID-19 Featured Story | By Eric Sagonowsky With leading COVID-19 vaccines in late-stage testing, companies have been inking supply deals with the U.S. government for a quick rollout if their programs succeed. Now, Johnson & Johnson is getting into the act with a $1 billion agreement. read more |
| |
|---|
|
| | New vaccines will save lives. Who will save the vaccines? The world’s pharmaceutical cold chains do not at this time have the equipment and scale to safely and compliantly deliver a temperature-sensitive COVID-19 vaccine. Click to learn more about emerging trends in vaccine logistics and distribution.
*Republished with permission, this article first appeared on UPS’s thought leadership blog, Longitudes. |
Top Stories By Amirah Al Idrus As the quest for COVID-19 treatments continues, the National Institutes of Health (NIH) is starting an adaptive trial to test experimental antibody treatments for the disease. It’s starting with Eli Lilly and AbCellera’s candidate but could add more prospects as the trial goes on. read more By Tina Reed CVS Health earned $3 billion in profit for the first quarter, beating Wall Street expectations. read more By Eric Sagonowsky Unhappy with the price and availability of Gilead’s remdesivir—the only drug with FDA clearance to treat COVID-19—dozens of state attorneys general are calling on the federal government to use its power to bust the company's patents and open up broader production. read more By Staff Beating back the COVID-19 pandemic will take a massive effort by talented, dedicated people in biopharma and beyond. They're working now behind the scenes—scientists, researchers, manufacturing specialists, policy experts and many more—to deliver solutions. We aim to tell their stories in a special feature this fall. And we're looking for your nominations. read more By Angus Liu Moderna's charging between $32 to $37 per dose for its coronavirus shot, dubbed mRNA-1273, for some “smaller-volume” purchasers. That's almost twice what Pfizer and BioNTech offered the U.S. government for 100 million doses of their rival vaccine. Bigger buyers will get a “different ballpark” price, Moderna promised—but didn't say how different. read more By Paige Minemyer The COVID-19 pandemic is highlighting the strengths of Medicare Advantage, Humana executives said Wednesday. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Moderna's experimental vaccine protected mice in a challenge study, U.S. officials said. Wednesday, pricing for COVID-19 vaccines became clearer with developments from Johnson & Johnson and Moderna. And experts called for an end to harassment of public health officials during the pandemic. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Conor Hale The massive medtech deal reflects the growing importance of virtual healthcare platforms as the world is caught in the wake of the COVID-19 pandemic. read more By Angus Liu COVID-19 infects a person by first binding to the ACE2 receptor on the surface of healthy cells. Scientists led by University of Illinois, Urbana-Champaign, identified a variant of the receptor that might work as a therapeutic candidate by acting as a decoy to lure the virus away. read more By Nick Paul Taylor Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. The Indian company said the DNA vaccine was well tolerated in the first stage of the adaptive phase 1/2 trial it initiated last month. read more By Heather Landi A new survey sheds light on how Medicare-eligible seniors have embraced technology for their healthcare needs during the pandemic. Find out how much telehealth visits have soared among this population and the other ways seniors are using digital health tools. read more By Angus Liu Regeneron pulled off a 24% revenue increase on the strength of Eylea and Dupixent sales, as well as a U.S. government contract for its COVID-19 antibodies. The company expects initial clinical virology and biomarker results from the cocktail treatment in September. read more By Beth Snyder Bulik Finding patients with rare diseases is difficult enough, but even more so when diagnostics are needed to identify candidates. Bayer’s pharma chief said it's been a struggle to find patients for its NTRK cancer med Vitrakvi, with prospects not improving during the COVID-19 crisis—and the struggle is shared by other targeted oncology drugs. read more |
